C Bosetti1, V Rosato, S Gallus, J Cuzick, C La Vecchia. 1. Department of Epidemiology, Istituto di Ricerche Farmacologiche, Mario Negri, Milan, Italy. cristina.bosetti@marionegri.it
Abstract
BACKGROUND: Aspirin has been associated to a reduced risk of colorectal and possibly of a few other common cancers. METHODS: To provide an up-to-date quantification of this association, we conducted a meta-analysis of all observational studies on aspirin and 12 selected cancer sites published up to September 2011. RESULTS: Regular aspirin is associated with a statistically significant reduced risk of colorectal cancer [summary relative risk (RR) from random effects models = 0.73, 95% confidence interval (CI) 0.67-0.79], and of other digestive tract cancers (RR = 0.61, 95% CI = 0.50-0.76, for squamous cell esophageal cancer; RR = 0.64, 95% CI = 0.52-0.78, for esophageal and gastric cardia adenocarcinoma; and RR = 0.67, 95% CI = 0.54-0.83, for gastric cancer), with somewhat stronger reductions in risk in case-control than in cohort studies. Modest inverse associations were also observed for breast (RR = 0.90, 95% CI = 0.85-0.95) and prostate cancer (RR = 0.90, 95% CI = 0.85-0.96), while lung cancer was significantly reduced in case-control studies (0.73, 95% CI = 0.55-0.98) but not in cohort ones (RR = 0.98, 95% CI = 0.92-1.05). No meaningful overall associations were observed for cancers of the pancreas, endometrium, ovary, bladder, and kidney. CONCLUSIONS: Observational studies indicate a beneficial role of aspirin on colorectal and other digestive tract cancers; modest risk reductions were also observed for breast and prostate cancer. Results are, however, heterogeneous across studies and dose-risk and duration-risk relationships are still unclear.
BACKGROUND:Aspirin has been associated to a reduced risk of colorectal and possibly of a few other common cancers. METHODS: To provide an up-to-date quantification of this association, we conducted a meta-analysis of all observational studies on aspirin and 12 selected cancer sites published up to September 2011. RESULTS: Regular aspirin is associated with a statistically significant reduced risk of colorectal cancer [summary relative risk (RR) from random effects models = 0.73, 95% confidence interval (CI) 0.67-0.79], and of other digestive tract cancers (RR = 0.61, 95% CI = 0.50-0.76, for squamous cell esophageal cancer; RR = 0.64, 95% CI = 0.52-0.78, for esophageal and gastric cardia adenocarcinoma; and RR = 0.67, 95% CI = 0.54-0.83, for gastric cancer), with somewhat stronger reductions in risk in case-control than in cohort studies. Modest inverse associations were also observed for breast (RR = 0.90, 95% CI = 0.85-0.95) and prostate cancer (RR = 0.90, 95% CI = 0.85-0.96), while lung cancer was significantly reduced in case-control studies (0.73, 95% CI = 0.55-0.98) but not in cohort ones (RR = 0.98, 95% CI = 0.92-1.05). No meaningful overall associations were observed for cancers of the pancreas, endometrium, ovary, bladder, and kidney. CONCLUSIONS: Observational studies indicate a beneficial role of aspirin on colorectal and other digestive tract cancers; modest risk reductions were also observed for breast and prostate cancer. Results are, however, heterogeneous across studies and dose-risk and duration-risk relationships are still unclear.
Authors: Vikrant V Sahasrabuddhe; Munira Z Gunja; Barry I Graubard; Britton Trabert; Lauren M Schwartz; Yikyung Park; Albert R Hollenbeck; Neal D Freedman; Katherine A McGlynn Journal: J Natl Cancer Inst Date: 2013-05-01 Impact factor: 13.506
Authors: Haejin In; Marisa Langdon-Embry; Lauren Gordon; Clyde B Schechter; Judith Wylie-Rosett; Philip E Castle; M Margaret Kemeny; Bruce D Rapkin Journal: J Surg Res Date: 2018-04-03 Impact factor: 2.192
Authors: YongLi Ji; Tiffany Rounds; Abigail Crocker; Betsy Sussman; Russell C Hovey; Fonda Kingsley; Hyman B Muss; Judy E Garber; Marie E Wood Journal: Cancer Prev Res (Phila) Date: 2016-02-23
Authors: Stephen P Fink; Mai Yamauchi; Reiko Nishihara; Seungyoun Jung; Aya Kuchiba; Kana Wu; Eunyoung Cho; Edward Giovannucci; Charles S Fuchs; Shuji Ogino; Sanford D Markowitz; Andrew T Chan Journal: Sci Transl Med Date: 2014-04-23 Impact factor: 17.956
Authors: Erika K S M Leenders; Harm Westdorp; Roger J Brüggemann; Jan Loeffen; Christian Kratz; John Burn; Nicoline Hoogerbrugge; Marjolijn C J Jongmans Journal: Eur J Hum Genet Date: 2018-06-14 Impact factor: 4.246